Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug PharmaphorumCelcuity has won FDA approval for gedatolisib - its first product - as a treatment for patients with a particular form of breast cancer.OncologyRead full story pharminent July 15, 2026 (Last updated: July 16, 2026) Pharmaphorum Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of breast cancer. Oncology Read full story Post navigation Previous: Biogen’s Tau-Targeting Alzheimer’s Data Show Promise — and Raise QuestionsNext: AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026